placebo + pramlintide

placebo + pramlintide refers to a specific treatment regimen evaluated in clinical studies, notably by AstraZeneca (following the acquisition of Amylin Pharmaceuticals), for the management of obesity and overweight. This regimen consists of the active drug pramlintide administered alongside a placebo, which serves as a control for a second active agent (typically metreleptin) in combination trials. Pramlintide is a synthetic analog of the human hormone amylin. It functions as an amylin receptor agonist, mimicking the effects of endogenous amylin by slowing gastric emptying, inhibiting postprandial glucagon secretion, and promoting satiety via central nervous system signaling. The study of this combination was part of an effort to identify synergistic effects between amylin and leptin pathways for weight reduction, although the specific combination with metreleptin was not pursued to approval for obesity.

Brand names

Symlin

Other names

pramlintide acetate + placebopramlintide + placebo